Cencora, Inc. (COR)

FY2025 revenue exceeded $280B, driven by GLP-1 drug distribution volume and specialty pharma growth. However, gross margins are ~3-4%, so revenue growth overstates the economic reality. Operating income growth of ~8-10% is more meaningful and competitive with McKesson.

Cencora holds ~33% of the US pharmaceutical distribution market in a stable oligopoly. Market share shifts are glacial in this industry — switching distributors is operationally disruptive for pharmacies and health systems. The company is gaining share in specialty distribution through its Alliance Healthcare international platform.

Limited direct pricing power. Distribution fees are negotiated with large pharmacy chains (Walgreens is COR's largest customer at ~30% of revenue) and drug manufacturers. The company earns incremental margin on generic drugs where it can capture spread, but branded drug distribution is essentially a cost-plus utility.

Cencora's investments in specialty drug logistics, cold-chain capabilities for biologics, and cell/gene therapy distribution are positioning the company for the higher-margin future of pharma. These are the right bets but execution takes time and capital.

Pharmacies and health systems are deeply integrated with their distributor's ordering systems, delivery logistics, and rebate structures. Switching costs are high in terms of operational disruption and potential inventory issues. However, large customers like Walgreens have leverage to renegotiate terms.

Modest scale-driven network effects. The larger the distribution network, the more efficient routes and warehouse utilization become. But this is a scale advantage, not a true network effect — Cencora's product doesn't become more valuable to customers as more pharmacies use it.

DEA licensing, state pharmacy board regulations, and the complex compliance requirements for controlled substance distribution create significant barriers to entry. No new national-scale pharma distributor has emerged in decades. The regulatory moat is real but also creates liability exposure (opioid litigation).

The distribution infrastructure — warehouses, cold chain, delivery fleet, IT systems — requires billions in investment that would be uneconomic for a new entrant to replicate at scale. Cencora generates $3B+ in annual free cash flow on this asset base.

FY2026 EPS estimates have been revised up ~5-7% on better specialty distribution margins and continued GLP-1 volume tailwinds. The street is incrementally more positive but the stock rarely sees aggressive upward revisions given the predictable nature of the business.

The GLP-1/obesity drug distribution theme provides a positive narrative. However, ongoing opioid settlement payments (~$6.4B total), drug pricing reform threats from Washington, and the mundane perception of distribution businesses keep a ceiling on sentiment.

Management has been competent stewards — consistent buybacks, modest dividend growth, and the strategic rebrand from AmerisourceBergen to Cencora. International expansion through Alliance Healthcare is reasonable. Nothing spectacular, nothing concerning.